Last update 21 Nov 2024
REGN-5714
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms Anti-Bet v 1 Monoclonal Antibodies |
Target |
Mechanism Bet v 1 inhibitors(Bet v 1 Protein inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Gene Sequence
Sequence Code 319240661CDR1-LCDR3-L
Sequence Code 319240707CDR2-H
Sequence Code 319240641VH
Sequence Code 17330CDR1-LCDR3-L
Sequence Code 319240656VH
Sequence Code 43789VL
Sequence Code 319240660CDR1-L
Sequence Code 2171CDR1-LCDR2-L
Sequence Code 159499CDR1-H
Sequence Code 9822999CDR2-H
Sequence Code 29028CDR1-L
Sequence Code 319240658CDR3-H
Sequence Code 319240716H
Sequence Code 319240642CDR2-H
Sequence Code 319240721L
Sequence Code 319240708CDR3-H
Sequence Code 2278CDR1-LCDR2-L
Sequence Code 319240705VH
Sequence Code 319240720H
Sequence Code 1146474L
Sequence Code 319240643CDR3-H
Sequence Code 319240659VL
Sequence Code 319240722H
Sequence Code 319240706CDR1-H
Sequence Code 319240717L
Sequence Code 10217CDR1-LCDR2-L
Sequence Code 38899CDR1-L
Sequence Code 319240645CDR1-LCDR3-L
Sequence Code 319240644VL
Sequence Code 319240657CDR1-H
Related
4
Clinical Trials associated with REGN-5714A Two-Part Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy of the Anti-Bet v 1 Monoclonal Antibodies to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy of Anti-Bet v 1 Monoclonal Antibodies to Reduce Symptoms of Seasonal Allergic Rhinitis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy of Anti-Bet v 1 Monoclonal Antibodies to Reduce Symptoms of Seasonal Allergic Rhinitis
100 Clinical Results associated with REGN-5714
Login to view more data
100 Translational Medicine associated with REGN-5714
Login to view more data
100 Patents (Medical) associated with REGN-5714
Login to view more data
7
Literatures (Medical) associated with REGN-571402 Oct 2018Analytical ChemistryQ1 · CHEMISTRY
Epitope Mapping by HDX-MS Elucidates the Surface Coverage of Antigens Associated with High Blocking Efficiency of Antibodies to Birch Pollen Allergen
Q1 · CHEMISTRY
Article
Author: Yang, Janice ; Olson, William ; Zhang, Qian ; Badithe, Ashok ; Liu, Yashu ; Bautista, Joannie
01 Jan 2006Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M
Clinical evaluation of recombinant allergens.
Article
Author: Cromwell, Oliver ; Narkus, Annemie
01 Jan 2006Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M
Validation of quantitative, allergen-specific ELISAs.
Article
Author: Monsalve, Rafael ; Raulf-Heimsoth, Monika ; Fiebig, Helmut ; Fötisch, Kay ; Vieths, Stefan ; Barber, Domingo ; Moingeon, Philippe ; Weber, Bernhard ; di Felice, Gabriella ; Becker, Wolf-Meinhard ; Cromwell, Oliver ; Pini, Carlo ; van Ree, Ronald ; Didierlaurent, Alain
100 Deals associated with REGN-5714
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Conjunctivitis | Phase 3 | CA | 14 Jan 2021 | |
| Conjunctivitis | Phase 3 | DE | 14 Jan 2021 | |
| Conjunctivitis | Phase 3 | DK | 14 Jan 2021 | |
| Conjunctivitis | Phase 3 | BE | 14 Jan 2021 | |
| Conjunctivitis | Phase 3 | US | 14 Jan 2021 | |
| Rhinitis, Allergic, Seasonal | Phase 3 | DK | 14 Jan 2021 | |
| Rhinitis, Allergic, Seasonal | Phase 3 | DE | 14 Jan 2021 | |
| Rhinitis, Allergic, Seasonal | Phase 3 | BE | 14 Jan 2021 | |
| Rhinitis, Allergic, Seasonal | Phase 3 | CA | 14 Jan 2021 | |
| Rhinitis, Allergic, Seasonal | Discovery | US | 14 Jan 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 3 | 353 | ajzbzevolt(yxegmiixsp) = linflzzycl jgzidfgnsq (gvlovefufm, oopfilbeqj - eeyvlwxdhn) View more | - | 27 Oct 2022 | |||
Placebo (Placebo Only) | ajzbzevolt(yxegmiixsp) = mizhwutpmx jgzidfgnsq (gvlovefufm, odmkujhdho - kqbuchhskk) View more | ||||||
Phase 1 | 96 | (mnscljcgjj) = fhutonvmsz wqryhopygu (eoeteqatub ) View more | Positive | 11 Jun 2021 | |||
Placebo | - | ||||||
Not Applicable | - | wdtmvprnxh(labjevpcvc) = ssbnotgyga dpghcafdja (nbjjykndsd ) | - | 01 Feb 2020 | |||
wdtmvprnxh(labjevpcvc) = wufyqaaivs dpghcafdja (nbjjykndsd ) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free